EGFR and non-small cell lung carcinoma: There is limited knowledge about the predictive value of DCE-MRI and DWI in evaluating the therapeutic effects of WBRT in combination with EGFR-TKI (gefitinib) on NSCLC patients with brain metastasis and was thus chosen as the focus of the present study.